| ID: | 175 | |
|---|---|---|
| Name: | Compound 175 | |
| Description: | Original numeration in publication: 15 | |
| Labels: | Test_set, Thiazolidine-2, 4-dione | |
| CAS: | ||
| InChi Code: | InChI=1S/C23H21Cl2N3O4S/c1-2-3-10-26-21(30)14-5-8-17(9-6-14)27-20(29)13-28-22(31)19(33-23(28)32)11-15-4-7-16(24)12-18(15)25/h4-9,11-12H,2-3,10,13H2,1H3,(H,26,30)(H,27,29)/b19-11- |
pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]
| Value | Source or prediction |
|---|---|
| 6.7 |
El-Adl, K.; El-Helby, A.-G. A.; Sakr, H. a. A., R. R.; Mahdy, H. A.; Nasser, M. a. A., H. S.; El-Hddad, S. S. A. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2021, 354, e2000279. https://doi.org/10.1002/ardp.202000279 |
| 6.26769 |
Eq1: VEGFR-2 inhibition (Data used to validate model) |